Nan Fung Group Reduces Oculis Stake Amid Challenges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 08 2026
0mins
Source: Fool
- Share Reduction Details: Nan Fung Group reduced its Oculis stake by 163,957 shares in Q1 2026, valued at approximately $4.3 million, indicating a routine portfolio adjustment rather than a loss of confidence in the company.
- Holding Value Analysis: At quarter-end, Nan Fung retained 350,745 shares of Oculis, valued at $9.3 million, representing 7.7% of its total AUM, highlighting Oculis's significance in its investment portfolio.
- Company Financial Status: Oculis has a market capitalization of $677 million, facing a net loss of $94.6 million; however, as of March 31, 2026, it reported $277.6 million in cash and short-term investments, providing a runway into the second half of 2029.
- R&D Progress and Challenges: Following the failure of its Phase 3 trials for OCS-01 in May 2026, Oculis's stock price has dropped about 43% over the past year, prompting a shift in focus to its remaining programs, Privosegtor and Licaminlimab, with investors needing to watch for upcoming data updates.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OCS
Wall Street analysts forecast OCS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 11.300
Low
29.00
Averages
40.00
High
55.00
Current: 11.300
Low
29.00
Averages
40.00
High
55.00
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Oculis Under Investigation After 23.44% Stock Drop Following Trial Failures
- Stock Price Plunge: On May 29, 2026, Oculis announced the failure of two late-stage trials for its lead candidate OCS-01 targeting diabetic macular edema, resulting in a stock price drop of $6.95, or 23.44%, closing at $22.70 per share, reflecting market pessimism regarding its future prospects.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Oculis and certain officers have engaged in securities fraud or other unlawful business practices, with investors advised to contact the firm for information on joining the class action, potentially further damaging the company's reputation and shareholder confidence.
- Impact of Trial Failures: The failure of Oculis's Phase 3 DIAMOND-1 and DIAMOND-2 trials signifies a major setback in its R&D pipeline, raising investor concerns about the company's future research capabilities, which could affect its financing and competitive position in the market.
- Industry Reaction: This incident has heightened market awareness of risks in the biopharmaceutical sector, as trust in related companies may decline following clinical trial failures, potentially impacting overall investment enthusiasm and capital inflows into the industry.
See More
Oculis to Present at Clinical Trials Summit 2026 on Neuroprotective Therapy
- Summit Presentation: Oculis will present at the Clinical Trials Summit 2026 on June 12-13 in Las Vegas, highlighting the development journey of Privosegtor, which aims to address significant unmet medical needs in optic neuritis as a potential first neuroprotective therapy.
- Breakthrough Progress: Following the successful Phase 2 ACUITY trial, Privosegtor has received Breakthrough Therapy designation from the FDA and PRIME designation from the EMA, marking a significant milestone in the treatment of optic neuropathies and offering new therapeutic options for patients.
- Clinical Data Support: The ACUITY trial demonstrated Privosegtor's neuroprotective potential by improving visual function and preserving retinal structure, with consistent efficacy observed in animal models, indicating its broad applicability in various neuro-ophthalmic diseases.
- Market Opportunity and Strategic Direction: Oculis' PIONEER program includes registrational trials for optic neuritis and non-arteritic anterior ischemic optic neuropathy, which are expected to enhance the company's market opportunities in neuro-ophthalmology and solidify its leadership position in the industry.
See More
Oculis Under Investigation After 23.44% Stock Drop Following Trial Failures
- Stock Price Plunge: Oculis Holding AG announced on May 29, 2026, that its lead candidate OCS-01 failed to meet primary endpoints in two late-stage trials for diabetic macular edema, resulting in a stock price drop of $6.95, or 23.44%, closing at $22.70 per share, significantly undermining investor confidence.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Oculis and certain executives engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, which could lead to potential legal liabilities and financial repercussions for the company.
- Impact of Trial Failures: The failure of Oculis's DIAMOND-1 and DIAMOND-2 trials not only tarnishes the company's market reputation but may also reduce future financing and partnership opportunities, exacerbating investor anxiety and uncertainty about the company's prospects.
- Industry Reaction: This incident has sparked market concerns regarding the success rates of clinical trials in the biopharmaceutical sector, leading investors to adopt a more cautious approach to investments in similar companies, potentially affecting capital flows and innovation capabilities across the industry.
See More
Oculis Launches Genotype Trial for Dry Eye Disease
- Trial Initiation: Oculis has announced the launch of the first genotype-based registrational trial, PREDICT-1, in dry eye disease (DED), with the first patient randomized, marking a significant advancement in precision medicine treatment.
- Patient Recruitment: The trial plans to enroll approximately 160 patients, with about two-thirds carrying the specific TNFR1 genotype, aiming to evaluate the efficacy and safety of Licaminlimab, particularly in genotype-positive patients.
- Market Demand: Approximately 10 million patients in the U.S. suffer from moderate to severe DED, with current treatment methods showing low efficacy, as only 13% of patients experience sustained relief, highlighting the urgent need for targeted therapies.
- Therapeutic Potential: Licaminlimab, an anti-TNFα eye drop, if approved, is expected to significantly improve symptoms for DED patients through a precision medicine approach, potentially transforming the current treatment paradigm.
See More
Oculis Highlights Breakthrough Therapies at Goldman Sachs Healthcare Conference
- Drug Development Progress: Oculis' Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA, targeting optic neuritis in the PIONEER registration program, which is expected to address a market opportunity exceeding $7 billion, showcasing the company's strong potential in neuro-ophthalmology.
- Precision Medicine Innovation: Licaminlimab is being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine for dry eye disease, marking Oculis' innovative efforts in treating dry eye, which could significantly enhance patient quality of life.
- Financial Strength: With a robust balance sheet and advanced pipeline, Oculis is poised to deliver several pivotal clinical trial results with current funding, further solidifying its position in the biopharmaceutical industry.
- Investor Engagement: Oculis will hold one-on-one investor meetings at the Goldman Sachs Healthcare Conference on June 9, showcasing its innovative product portfolio and aiming to attract potential investors, thereby enhancing market confidence through transparent communication.
See More
Oculis Under Investigation for Securities Violations Affecting Shareholder Rights
- Investigation Launched: The Schall Law Firm has initiated an investigation into Oculis Holding AG regarding potential violations of securities laws, focusing on whether the company issued false or misleading statements that may have harmed shareholder rights.
- Clinical Trial Failures: Oculis claimed its Phase 3 DIAMOND trials were “advancing as planned,” but announced on May 29, 2026, that both trials failed to meet their primary endpoints, directly impacting the company's future drug application prospects.
- FDA Filing Abandonment: Following the disappointing DIAMOND trial results, Oculis has decided not to pursue an FDA filing for its drug candidate, a move that could lead to decreased investor confidence and negatively affect the company's stock price.
- Shareholder Rights Advocacy: The Schall Law Firm encourages affected shareholders to reach out to discuss their rights, demonstrating a commitment to investor protection and potentially prompting more shareholders to engage in litigation for compensation.
See More
Oculis Under Investigation After 23.44% Stock Drop Following Trial Failures
- Stock Price Plunge: On May 29, 2026, Oculis announced the failure of two late-stage trials for its lead candidate OCS-01 targeting diabetic macular edema, resulting in a stock price drop of $6.95, or 23.44%, closing at $22.70 per share, reflecting market pessimism regarding its future prospects.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Oculis and certain officers have engaged in securities fraud or other unlawful business practices, with investors advised to contact the firm for information on joining the class action, potentially further damaging the company's reputation and shareholder confidence.
- Impact of Trial Failures: The failure of Oculis's Phase 3 DIAMOND-1 and DIAMOND-2 trials signifies a major setback in its R&D pipeline, raising investor concerns about the company's future research capabilities, which could affect its financing and competitive position in the market.
- Industry Reaction: This incident has heightened market awareness of risks in the biopharmaceutical sector, as trust in related companies may decline following clinical trial failures, potentially impacting overall investment enthusiasm and capital inflows into the industry.
See More
Oculis to Present at Clinical Trials Summit 2026 on Neuroprotective Therapy
- Summit Presentation: Oculis will present at the Clinical Trials Summit 2026 on June 12-13 in Las Vegas, highlighting the development journey of Privosegtor, which aims to address significant unmet medical needs in optic neuritis as a potential first neuroprotective therapy.
- Breakthrough Progress: Following the successful Phase 2 ACUITY trial, Privosegtor has received Breakthrough Therapy designation from the FDA and PRIME designation from the EMA, marking a significant milestone in the treatment of optic neuropathies and offering new therapeutic options for patients.
- Clinical Data Support: The ACUITY trial demonstrated Privosegtor's neuroprotective potential by improving visual function and preserving retinal structure, with consistent efficacy observed in animal models, indicating its broad applicability in various neuro-ophthalmic diseases.
- Market Opportunity and Strategic Direction: Oculis' PIONEER program includes registrational trials for optic neuritis and non-arteritic anterior ischemic optic neuropathy, which are expected to enhance the company's market opportunities in neuro-ophthalmology and solidify its leadership position in the industry.
See More
Oculis Under Investigation After 23.44% Stock Drop Following Trial Failures
- Stock Price Plunge: Oculis Holding AG announced on May 29, 2026, that its lead candidate OCS-01 failed to meet primary endpoints in two late-stage trials for diabetic macular edema, resulting in a stock price drop of $6.95, or 23.44%, closing at $22.70 per share, significantly undermining investor confidence.
- Legal Investigation Launched: Pomerantz LLP is investigating whether Oculis and certain executives engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, which could lead to potential legal liabilities and financial repercussions for the company.
- Impact of Trial Failures: The failure of Oculis's DIAMOND-1 and DIAMOND-2 trials not only tarnishes the company's market reputation but may also reduce future financing and partnership opportunities, exacerbating investor anxiety and uncertainty about the company's prospects.
- Industry Reaction: This incident has sparked market concerns regarding the success rates of clinical trials in the biopharmaceutical sector, leading investors to adopt a more cautious approach to investments in similar companies, potentially affecting capital flows and innovation capabilities across the industry.
See More
Oculis Launches Genotype Trial for Dry Eye Disease
- Trial Initiation: Oculis has announced the launch of the first genotype-based registrational trial, PREDICT-1, in dry eye disease (DED), with the first patient randomized, marking a significant advancement in precision medicine treatment.
- Patient Recruitment: The trial plans to enroll approximately 160 patients, with about two-thirds carrying the specific TNFR1 genotype, aiming to evaluate the efficacy and safety of Licaminlimab, particularly in genotype-positive patients.
- Market Demand: Approximately 10 million patients in the U.S. suffer from moderate to severe DED, with current treatment methods showing low efficacy, as only 13% of patients experience sustained relief, highlighting the urgent need for targeted therapies.
- Therapeutic Potential: Licaminlimab, an anti-TNFα eye drop, if approved, is expected to significantly improve symptoms for DED patients through a precision medicine approach, potentially transforming the current treatment paradigm.
See More
Oculis Highlights Breakthrough Therapies at Goldman Sachs Healthcare Conference
- Drug Development Progress: Oculis' Privosegtor has received Breakthrough Therapy designation from the FDA and Priority Medicines designation from the EMA, targeting optic neuritis in the PIONEER registration program, which is expected to address a market opportunity exceeding $7 billion, showcasing the company's strong potential in neuro-ophthalmology.
- Precision Medicine Innovation: Licaminlimab is being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine for dry eye disease, marking Oculis' innovative efforts in treating dry eye, which could significantly enhance patient quality of life.
- Financial Strength: With a robust balance sheet and advanced pipeline, Oculis is poised to deliver several pivotal clinical trial results with current funding, further solidifying its position in the biopharmaceutical industry.
- Investor Engagement: Oculis will hold one-on-one investor meetings at the Goldman Sachs Healthcare Conference on June 9, showcasing its innovative product portfolio and aiming to attract potential investors, thereby enhancing market confidence through transparent communication.
See More
Oculis Under Investigation for Securities Violations Affecting Shareholder Rights
- Investigation Launched: The Schall Law Firm has initiated an investigation into Oculis Holding AG regarding potential violations of securities laws, focusing on whether the company issued false or misleading statements that may have harmed shareholder rights.
- Clinical Trial Failures: Oculis claimed its Phase 3 DIAMOND trials were “advancing as planned,” but announced on May 29, 2026, that both trials failed to meet their primary endpoints, directly impacting the company's future drug application prospects.
- FDA Filing Abandonment: Following the disappointing DIAMOND trial results, Oculis has decided not to pursue an FDA filing for its drug candidate, a move that could lead to decreased investor confidence and negatively affect the company's stock price.
- Shareholder Rights Advocacy: The Schall Law Firm encourages affected shareholders to reach out to discuss their rights, demonstrating a commitment to investor protection and potentially prompting more shareholders to engage in litigation for compensation.
See More
